Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464
After the second year of continued treatment, 69% of patients were in clinical remission and 94% benefited from a clinical response
Readings of the endoscopies were performed centrally by independent reviewers; Median fecal calprotectin (31.6 μg/g) was in the normal range
Patient enrollment for ongoing Phase 2b ulcerative colitis trial is on track, with 69% (159/232) of patients randomized to date and recruitment expected to be completed by the end of 2020 and expected results in Q2/2021
Abivax is currently preparing all required steps to advance ABX464 into UC Phase 3
